Two developments from earlier this year that deserve more attention than they've received.
## Compass Moves Into PTSD
Compass Pathways has been running Phase 3 trials of its synthetic psilocybin compound COMP360 for treatment-resistant depression. In January 2026, the FDA cleared a new Investigational New Drug application allowing the company to expand into PTSD, [according to Lucid News](https://www.lucid.news/legislation-industry-and-the-future-of-psilocybin-for-ptsd/).
PTSD is a meaningful expansion. The existing COMP360 evidence base is in treatment-resistant depression — a population where current options are genuinely limited but where psilocybin is competing against other emerging treatments. PTSD has fewer approved options, larger unmet need, and a politically sympathetic patient population (particularly veterans) that has driven significant bipartisan legislative attention.
Compass hasn't published a trial registration for the PTSD program yet. We'll link to the ClinicalTrials entry when it's live.
## Public Support for Psilocybin Mirrors Cannabis in the Mid-90s
A [new RAND Corporation survey](https://www.lucid.news/rand-report-therapeutic-use-us-views-psychedelics/) polled 10,122 US adults between September and October 2025. The headline finding: roughly 25% of Americans now support the legal use of psilocybin mushrooms.
The RAND researchers note that this number mirrors where cannabis polling stood in the mid-1990s — shortly before the first state medical marijuana laws passed and public support began its sustained climb.
Some caveats worth noting. This is the first probability-based national poll to ask about specific psychedelic compounds rather than grouping them together — prior polling lumped psilocybin, MDMA, and LSD under a single umbrella, which obscures meaningful variation in public attitudes. Support for psilocybin substantially outpaces support for MDMA and LSD in this data. And across all compounds, support is strongly conditional on clinical oversight. Americans aren't broadly in favor of recreational legalization — they're increasingly open to medically supervised use.